Parkinson's UK responds to Pfizer's announcement on research funding
Pfizer is to cease funding Parkinson's research.
Responding to Pfizer's decision, Dr Arthur Roach, Director of Research at Parkinson’s UK, said:
"While we are disappointed by Pfizer’s announcement, Parkinson’s UK will continue to work with urgency and determination in partnership with other pharmaceutical companies to create and develop new treatments on behalf of people with Parkinson's everywhere.
"We know, from our work with pharmaceutical companies across the globe, that there are many others still ready to devote tremendous time, effort and funding towards the development of better treatments for Parkinson's.
"For instance, our tireless work with the 9 pharmaceutical companies who are members of our Critical Path for Parkinson’s consortium is helping smooth the path for all future drugs by making clinical trials smarter and faster.
"Pharmaceutical companies regularly review their research efforts and spend in different areas and moves like this are not uncommon. That does not shake Parkinson's UK's commitment to research that will bring forward the day when no one fears Parkinson's."
For more information please contact:
Molly Horsburgh, Senior Media and PR Officer, Parkinson’s UK:
0207 963 9351 or 07961 460248 (out of hours)
Every hour, 2 people in the UK are told they have Parkinson's.
It affects 145,000 people in the UK – which is around 1 in 350 of the adult population.
Parkinson's is a degenerative neurological condition, for which there currently is no cure. The main symptoms of the condition are tremor, slowness of movement and rigidity.
For advice, information and support, visit www.parkinsons.org.uk or call our free, confidential helpline on 0808 800 0303.